For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com.

"We are pleased that our sub-licensee, DyDo, has launched FIRDAPSE in Japan. We believe in health equity, and this launch is a testament to our ongoing efforts to increase patient access to life ...

Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Japan, DyDo Pharma has launched FIRDAPSE Tablets 10 mg in Japan for the ...

FIRDAPSE® is currently the only U.S. FDA-approved therapy for LEMS in adults and pediatric patients six years of age and older. The launch in Japan is part of Catalyst's mission to expand patient ...

CORAL GABLES, Fla. - Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), a pharmaceutical company demonstrating excellent financial ...

CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for epilepsy. Detailed revenue breakdown from Q3 2024 10-Q highlights FIRDAPSE as the main revenue driver.

Catalyst Pharmaceuticals, Inc. announced that its sub-licensee, DyDo Pharma, has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan, aimed at improving muscle weakness in patients with ...

(RTTNews) - Catalyst Pharmaceuticals, Inc. (CPRX), a commercial-stage biopharmaceutical company, Tuesday announced that its sub-licensee, DyDo Pharma, has launched FIRDAPSE or amifampridine ...